Koch Joachim, Tesar Michael
Affimed GmbH, Technologiepark, Heidelberg, Germany.
Transfus Med Hemother. 2017 Sep;44(5):337-350. doi: 10.1159/000479981. Epub 2017 Sep 11.
Immunotherapy has the potential to support and expand the body's own armamentarium of immune effector functions, which have been circumvented during malignant transformation and establishment of cancer and is presently considered to be the most promising treatment option for cancer patients. Recombinant antibody technologies have led to a multitude of novel antibody formats, which are in clinical development and hold great promise for future therapies. Among these formats, bispecific antibodies are extremely versatile due to their high efficacy to recruit and activate anti-tumoral immune effector cells, their excellent safety profile, and the opportunity for use in combination with cellular therapies. This review article summarizes the latest developments in cancer immunotherapy using immuno-engagers for recruiting T cells and NK cells to the tumor site. In addition to antibody formats, malignant cell targets, and immune cell targets, opportunities for combination therapies, including check point inhibitors, cytokines and adoptive transfer of immune cells, will be summarized and discussed.
免疫疗法有潜力支持并扩展人体自身的免疫效应功能武器库，这些功能在恶性转化和癌症形成过程中被规避，目前被认为是癌症患者最有前景的治疗选择。重组抗体技术已产生了多种新型抗体形式，它们正处于临床开发阶段，对未来治疗极具前景。在这些形式中，双特异性抗体极其通用，因为它们在招募和激活抗肿瘤免疫效应细胞方面具有高效性、具有出色的安全性，并且有机会与细胞疗法联合使用。这篇综述文章总结了使用免疫衔接器将T细胞和NK细胞募集到肿瘤部位的癌症免疫疗法的最新进展。除了抗体形式、恶性细胞靶点和免疫细胞靶点外，还将总结和讨论联合疗法的机会，包括检查点抑制剂、细胞因子和免疫细胞的过继转移。
